SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    R.T. Bartus, J.H. Kordower, E.M. Johnson, L. Brown, B.R. Kruegel, Y. Chu, T.L. Baumann, A.E. Lang, C.W. Olanow, C.D. Herzog, Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with α-synucleinopathies, Neurobiology of Disease, 2015, 78, 162

    CrossRef

  2. 2
    Romina Aron Badin, Marta Vadori, Emanuele Cozzi, Philippe Hantraye, Translational research for Parkinson׳s disease: The value of pre-clinical primate models, European Journal of Pharmacology, 2015,

    CrossRef

  3. 3
    Weidong Le, Pavani Sayana, Joseph Jankovic, Animal Models of Parkinson’s Disease: A Gateway to Therapeutics?, Neurotherapeutics, 2014, 11, 1, 92

    CrossRef

  4. 4
    S E Gombash, F P Manfredsson, R J Mandel, T J Collier, D L Fischer, C J Kemp, N M Kuhn, S L Wohlgenant, S M Fleming, C E Sortwell, Neuroprotective potential of pleiotrophin overexpression in the striatonigral pathway compared with overexpression in both the striatonigral and nigrostriatal pathways, Gene Therapy, 2014, 21, 7, 682

    CrossRef

  5. 5
    Raymond T Bartus, Marc S Weinberg, R. Jude Samulski, Parkinson’s Disease Gene Therapy: Success by Design Meets Failure by Efficacy, Molecular Therapy, 2014, 22, 3, 487

    CrossRef

  6. 6
    Julia Tereshchenko, Andrea Maddalena, Mathias Bähr, Sebastian Kügler, Pharmacologically controlled, discontinuous GDNF gene therapy restores motor function in a rat model of Parkinson's disease, Neurobiology of Disease, 2014, 65, 35

    CrossRef

  7. 7
    Shane V. Hegarty, Aideen M. Sullivan, Gerard W. O’Keeffe, Roles for the TGFβ Superfamily in the Development and Survival of Midbrain Dopaminergic Neurons, Molecular Neurobiology, 2014, 50, 2, 559

    CrossRef

  8. 8
    Massimo S. Fiandaca, Howard J. Federoff, Using viral-mediated gene delivery to model Parkinson's disease: Do nonhuman primate investigations expand our understanding?, Experimental Neurology, 2014, 256, 117

    CrossRef

  9. 9
    A. Dhanushkodi, E. O. Akano, E. E. Roguski, Y. Xue, S. K. Rao, S. G. Matta, T. S. Rex, M. P. McDonald, A single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism, Genes, Brain and Behavior, 2013, 12, 2
  10. 10
    Patrick Hickey, Mark Stacy, AAV2-neurturin (CERE-120) for Parkinson's disease, Expert Opinion on Biological Therapy, 2013, 13, 1, 137

    CrossRef

  11. 11
    Raymond T. Bartus, Tiffany L. Baumann, Lamar Brown, Brian R. Kruegel, Jeffrey M. Ostrove, Christopher D. Herzog, Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating “clinical proof-of-concept” for AAV-neurturin (CERE-120) in Parkinson's disease, Neurobiology of Aging, 2013, 34, 1, 35

    CrossRef

  12. 12
    Massimo S. Fiandaca, Robert M. Padilla, Ishmeal Conteh, Howard J. Federoff, Can population genomics guide future therapeutic gene transfer strategies for Parkinson’s disease?, Open Journal of Genetics, 2013, 03, 02, 19

    CrossRef

  13. 13
    Susanne Bäck, Johan Peränen, Emilia Galli, Päivi Pulkkila, Liina Lonka-Nevalaita, Tuulia Tamminen, Merja H. Voutilainen, Atso Raasmaja, Mart Saarma, Pekka T. Männistö, Raimo K. Tuominen, Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease, Brain and Behavior, 2013, 3, 2
  14. 14
    Elisa Piccinini, Nisse Kalkkinen, Mart Saarma, Pia Runeberg-Roos, Glial cell line-derived neurotrophic factor: Characterization of mammalian posttranslational modifications, Annals of Medicine, 2013, 45, 1, 66

    CrossRef

  15. 15
    Aleksandra Glavaski-Joksimovic, Martha C. Bohn, Mesenchymal stem cells and neuroregeneration in Parkinson's disease, Experimental Neurology, 2013, 247, 25

    CrossRef

  16. 16
    Jeffrey H. Kordower, Anders Bjorklund, Trophic Factor Gene Therapy for Parkinson's Disease, Movement Disorders, 2013, 28, 1
  17. 17
    Neil Issar, Joseph Neimat, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  18. 18
    Neil M. Issar, Joseph S. Neimat, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  19. 19
    Massimo S. Fiandaca, Krystof S. Bankiewicz, Howard J. Federoff, Gene Therapy for the Treatment of Parkinson’s Disease: The Nature of the Biologics Expands the Future Indications, Pharmaceuticals, 2012, 5, 12, 553

    CrossRef

  20. 20
    André Toulouse, Grace C. Collins, Aideen M. Sullivan, Neurotrophic Effects of Growth/Differentiation Factor 5 in a Neuronal Cell Line, Neurotoxicity Research, 2012, 21, 3, 256

    CrossRef

  21. 21
    Yoland Smith, Thomas Wichmann, Stewart A Factor, Mahlon R DeLong, Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa, Neuropsychopharmacology, 2012, 37, 1, 213

    CrossRef

  22. 22
    Wenju Wang, Maosheng Sun, Hongjun Li, Wanpu Wang, Min Yan, The delivery of tyrosine hydroxylase accelerates the neurorestoration of Macaca Rhesus model of Parkinson's disease provided by Neurturin, Neuroscience Letters, 2012, 524, 1, 10

    CrossRef

  23. 23
    Raymond T. Bartus, Translating the therapeutic potential of neurotrophic factors to clinical ‘proof of concept’: A personal saga achieving a career-long quest, Neurobiology of Disease, 2012, 48, 2, 153

    CrossRef

  24. 24
    Jennifer Witt, William J. Marks, An Update on Gene Therapy in Parkinson’s Disease, Current Neurology and Neuroscience Reports, 2011, 11, 4, 362

    CrossRef

  25. 25
    Agnieszka Ciesielska, Gabriele Mittermeyer, Piotr Hadaczek, Adrian P Kells, John Forsayeth, Krystof S Bankiewicz, Anterograde Axonal Transport of AAV2-GDNF in Rat Basal Ganglia, Molecular Therapy, 2011, 19, 5, 922

    CrossRef

  26. 26
    Raymond T. Bartus, Christopher D. Herzog, Yaping Chu, Alistair Wilson, Lamar Brown, Joao Siffert, Eugene M. Johnson, C. Warren Olanow, Elliott J. Mufson, Jeffrey H. Kordower, Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhuman primate brains, Movement Disorders, 2011, 26, 1
  27. 27
    Dustin R. Wakeman, Hemraj B. Dodiya, Jeffrey H. Kordower, Cell Transplantation and Gene Therapy in Parkinson's Disease, Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 2011, 78, 1
  28. 28
    Robert A. Hauser, Future Treatments for Parkinson's Disease: Surfing the PD Pipeline, International Journal of Neuroscience, 2011, 121, S2, 53

    CrossRef

  29. 29
    Christopher D. Herzog, Kathie M. Bishop, Lamar Brown, Alistair Wilson, Jeffrey H. Kordower, Raymond T. Bartus, Gene transfer provides a practical means for safe, long-term, targeted delivery of biologically active neurotrophic factor proteins for neurodegenerative diseases, Drug Delivery and Translational Research, 2011, 1, 5, 361

    CrossRef

  30. 30
    Miu Fei Lam, Meghan G. Thomas, Christopher R.P. Lind, Neurosurgical convection-enhanced delivery of treatments for Parkinson’s disease, Journal of Clinical Neuroscience, 2011, 18, 9, 1163

    CrossRef

  31. 31
    Aideen M. Sullivan, André Toulouse, Neurotrophic factors for the treatment of Parkinson's disease, Cytokine & Growth Factor Reviews, 2011, 22, 3, 157

    CrossRef

  32. 32
    Daniel E. Huddleston, Stewart A. Factor, Of Monkeys and Men: Analysis of the Phase 2 Double-Blind, Sham-Surgery Controlled, Randomized Trial of AAV2-Neurturin Gene Therapy for Parkinson’s Disease, Current Neurology and Neuroscience Reports, 2011, 11, 4, 345

    CrossRef

  33. 33
    Dali Yin, Francisco E. Valles, Massimo S. Fiandaca, John Bringas, Francisco Gimenez, Mitchel S. Berger, John Forsayeth, Krystof S. Bankiewicz, Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates, NeuroImage, 2011, 54, S196

    CrossRef

  34. 34
    Raymond T. Bartus, Lamar Brown, Alistair Wilson, Brian Kruegel, Joao Siffert, Eugene M. Johnson, Jeffrey H. Kordower, Christopher D. Herzog, Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease, Neurobiology of Disease, 2011, 44, 1, 38

    CrossRef

  35. 35
    Scellig Stone, Karim Mukhida, Andres M. Lozano, Youmans Neurological Surgery, 2011,

    CrossRef

  36. 36
    Reinhard Gabathuler, Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases, Neurobiology of Disease, 2010, 37, 1, 48

    CrossRef

  37. 37
    Helen L. Fitzsimons, Veronique Riban, Ross J. Bland, Jennifer L. Wendelken, Christine V. Sapan, Matthew J. During, Biodistribution and safety assessment of AAV2-GAD following intrasubthalamic injection in the rat, The Journal of Gene Medicine, 2010, 12, 4
  38. 38
    William J Marks, Raymond T Bartus, Joao Siffert, Charles S Davis, Andres Lozano, Nicholas Boulis, Jerrold Vitek, Mark Stacy, Dennis Turner, Leonard Verhagen, Roy Bakay, Raymond Watts, Barton Guthrie, Joseph Jankovic, Richard Simpson, Michele Tagliati, Ron Alterman, Matthew Stern, Gordon Baltuch, Philip A Starr, Paul S Larson, Jill L Ostrem, John Nutt, Karl Kieburtz, Jeffrey H Kordower, C Warren Olanow, Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial, The Lancet Neurology, 2010, 9, 12, 1164

    CrossRef

  39. 39
    Tomas Bjorklund, Jeffrey H. Kordower, Gene therapy for Parkinson's disease, Movement Disorders, 2010, 25, S1
  40. 40
    Wayne A. Cass, Laura E. Peters, Neurturin protects against 6-hydroxydopamine-induced reductions in evoked dopamine overflow in rat striatum, Neurochemistry International, 2010, 57, 5, 540

    CrossRef

  41. 41
    Toru Yasuda, Hideki Mochizuki, Use of growth factors for the treatment of Parkinson’s disease, Expert Review of Neurotherapeutics, 2010, 10, 6, 915

    CrossRef

  42. 42
    Suresh Babu Rangasamy, Katherine Soderstrom, Roy A.E. Bakay, Jeffrey H. Kordower, Recent Advances in Parkinson’S Disease - Translational and Clinical Research, 2010,

    CrossRef

  43. 43
    C. Warren Olanow, MOVEMENT DISORDERS 4, 2010,

    CrossRef

  44. 44
    Christopher D. Herzog, Lamar Brown, Dawn Gammon, Brian Kruegel, Richard Lin, Alistair Wilson, Ariadne Bolton, Marie Printz, Mehdi Gasmi, Kathie M. Bishop, Jeffrey H. Kordower, Raymond T. Bartus, EXPRESSION, BIOACTIVITY, AND SAFETY 1 YEAR AFTER ADENO-ASSOCIATED VIRAL VECTOR TYPE 2–MEDIATED DELIVERY OF NEURTURIN TO THE MONKEY NIGROSTRIATAL SYSTEM SUPPORT CERE-120 FOR PARKINSONʼS DISEASE, Neurosurgery, 2009, 64, 4, 602

    CrossRef

  45. 45
    Jamie L. Eberling, Adrian P. Kells, Philip Pivirotto, Janine Beyer, John Bringas, Howard J. Federoff, John Forsayeth, Krystof S. Bankiewicz, Functional Effects of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Parkinsonian Rhesus Monkeys, Human Gene Therapy, 2009, 20, 5, 511

    CrossRef

  46. 46
    Jonathan Kimmelman, Alex John London, Bernard Ravina, Tim Ramsay, Mark Bernstein, Alan Fine, Frank W. Stahnisch, Marina Elena Emborg, Launching invasive, first-in-human trials against Parkinson's disease: Ethical considerations, Movement Disorders, 2009, 24, 13
  47. 47
    Raymond T. Bartus, Reginald L. Dean, Pharmaceutical treatment for cognitive deficits in Alzheimer’s disease and other neurodegenerative conditions: exploring new territory using traditional tools and established maps, Psychopharmacology, 2009, 202, 1-3, 15

    CrossRef

  48. 48
    Tomas Björklund, Deniz Kirik, Scientific rationale for the development of gene therapy strategies for Parkinson's disease, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009, 1792, 7, 703

    CrossRef

  49. 49
    Dali Yin, Francisco E. Valles, Massimo S. Fiandaca, John Forsayeth, Paul Larson, Phillip Starr, Krystof S. Bankiewicz, Striatal volume differences between non-human and human primates, Journal of Neuroscience Methods, 2009, 176, 2, 200

    CrossRef

  50. 50
    Joseph C. Hsieh, Richard D. Penn, Neuromodulation, 2009,

    CrossRef

  51. 51
    Shilpa Ramaswamy, Katherine E. Soderstrom, Jeffrey H. Kordower, Neurotherapy: Progress in Restorative Neuroscience and Neurology, 2009,

    CrossRef

  52. 52
    Hideki Mochizuki, Toru Yasuda, M. Maral Mouradian, Advances in gene therapy for movement disorders, Neurotherapeutics, 2008, 5, 2, 260

    CrossRef

  53. 53
    Ole Isacson, Jeffrey H. Kordower, Future of cell and gene therapies for Parkinson's disease, Annals of Neurology, 2008, 64, S2
  54. 54
    R. Mark Richardson, Paul S. Larson, Krystof S. Bankiewicz, GENE AND CELL DELIVERY TO THE DEGENERATED STRIATUM, Neurosurgery, 2008, 63, 4, 629

    CrossRef

  55. 55
    Grégory Porras, Erwan Bezard, Preclinical development of gene therapy for Parkinson's disease, Experimental Neurology, 2008, 209, 1, 72

    CrossRef

  56. 56
    André Toulouse, Aideen M. Sullivan, Progress in Parkinson's disease—Where do we stand?, Progress in Neurobiology, 2008, 85, 4, 376

    CrossRef

  57. 57
    Peter A. LeWitt, Danette C. Taylor, Protection against Parkinson’s disease progression: Clinical experience, Neurotherapeutics, 2008, 5, 2, 210

    CrossRef

  58. 58
    William J Marks, Jill L Ostrem, Leonard Verhagen, Philip A Starr, Paul S Larson, Roy AE Bakay, Robin Taylor, Deborah A Cahn-Weiner, A Jon Stoessl, C Warren Olanow, Raymond T Bartus, Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial, The Lancet Neurology, 2008, 7, 5, 400

    CrossRef

  59. 59
    Jaan-Olle Andressoo, Mart Saarma, Signalling mechanisms underlying development and maintenance of dopamine neurons, Current Opinion in Neurobiology, 2008, 18, 3, 297

    CrossRef

  60. 60
    Eileen M. Denovan-Wright, Marissa Attis, Edgardo Rodriguez-Lebron, Ronald J. Mandel, Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice, Journal of Neuroscience Research, 2008, 86, 8
  61. 61
    Christopher D Herzog, Biplob Dass, Mehdi Gasmi, Roy Bakay, James E Stansell, Mark Tuszynski, Krystof Bankiewicz, Er-Yun Chen, Yaping Chu, Kathie Bishop, Jeffrey H Kordower, Raymond T Bartus, Transgene Expression, Bioactivity, and Safety of CERE-120 (AAV2-Neurturin) Following Delivery to the Monkey Striatum, Molecular Therapy, 2008, 16, 10, 1737

    CrossRef

  62. 62
    Amie L. Peterson, John G. Nutt, Treatment of Parkinson’s disease with trophic factors, Neurotherapeutics, 2008, 5, 2, 270

    CrossRef

  63. 63
    Eugene M. Johnson, Mark H. Tuszynski, CNS Regeneration, 2008,

    CrossRef

  64. 64
    Raymond T. Bartus, Christopher D. Herzog, Kathie Bishop, Jeffrey M. Ostrove, Mark Tuszynski, Jeffrey H. Kordower, Mehdi Gasmi, Issues regarding gene therapy products for Parkinson's disease: The development of CERE-120 (AAV-NTN) as one reference point, Parkinsonism & Related Disorders, 2007, 13, S469

    CrossRef

  65. 65
    Matthew J. Chiocco, Brandon K. Harvey, Yun Wang, Barry J. Hoffer, Neurotrophic factors for the treatment of Parkinson's disease, Parkinsonism & Related Disorders, 2007, 13, S321

    CrossRef